Stock CRVS CORVUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
1.53 USD +6.25% Intraday chart for Corvus Pharmaceuticals, Inc. +4.08% -13.07%
Apr. 09 Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis CI
Mar. 20 Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
AQ
Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
CI
Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating
MT
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2
MT
Transcript : Corvus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024
Corvus: Q4 Earnings Snapshot
AQ
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
AQ
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
AQ
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
CI
Sector Update: Health Care Stocks Mixed in Afternoon Trading
MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
MT
Corvus Pharmaceuticals Says Soquelitinib Received FDA Orphan Drug Designation
MT
Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation
DJ
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
AQ
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
AQ
Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRVS Stock
  4. News Corvus Pharmaceuticals, Inc.